Jin Cheng Pharmaceutical Completes Safety Certification Trials for Astaxanthin Project
SHANGHAI, CHINA – September 7, 2024– Jin Cheng Pharmaceutical (300233.SZ), a leading Chinese pharmaceutical company, has announced the completion of safety certification trials for its astaxanthin project. The company confirmed this news in an interaction with investors on its platform, stating that it is now actively pursuing regulatory approval for the product.
Astaxanthin is a powerful antioxidant known for its potential health benefits, including anti-inflammatory and immune-boosting properties. It is naturally found in certain algae and seafood, and is increasingly being explored for its applications in various industries, including pharmaceuticals, cosmetics, and food supplements.
Jin Cheng Pharmaceutical’s announcement comes as a significant development for the company, which has been actively investing in research and development of new products in recent years. The completion of safety certification trials marks a crucialstep towards bringing astaxanthin to the market.
We are pleased to announce the completion of safety certification trials for our astaxanthin project, said a spokesperson for Jin Cheng Pharmaceutical. This is a significant milestone for our company, and we are now actively working to secure regulatory approval for the product. We believethat astaxanthin has the potential to be a valuable addition to our product portfolio and to benefit consumers around the world.
The company also clarified that it does not currently have any monkeypox treatment products. This statement was made in response to a query from an investor, highlighting the company’s focus on its astaxanthin project.
The completion of safety certification trials is a positive sign for Jin Cheng Pharmaceutical, suggesting that the company is on track to launch its astaxanthin product. However, the company has not yet provided a timeline for regulatory approval or market launch.
Astaxanthin Market Potential
The global astax
Views: 0